**PGN-001** is an [[Adalimumab|adalimumab]] liquid formulation delivered via [[DDS|DDS]] capsule, developed by [[Biora Therapeutics]]. Considered a [[Combination Products|drug device combination]]. Expected to treat [[Ulcerative Colitis|ulcerative colitis]] as part of the [[Targeted Therapeutics Pipeline|Targeted Therapeutics Pipeline]]. > [!quote] PGN-001: Liquid formulation of Anti-TNF-alpha monoclonal antibody delivered with the DDS for the treatment of ulcerative colitis > We are developing PGN-001 as an orally-delivered variant of adalimumab for the treatment of ulcerative colitis (UC). Multiple anti-TNF-alpha targeting therapies have been approved for UC, but data suggests patients may not have enough drug in the tissue to engage the target, TNF-alpha, and reduce inflammation. We have developed our own anti-TNF-alpha antibody formulation for use in further development. > > PGN-001 is currently in preclinical stage development. We have conducted a series of preclinical studies demonstrating the potential of locally delivered anti-TNF-alpha antibodies to reduce disease burden in ulcerative colitis models. > > Source: <https://www.bioratherapeutics.com/pipeline/targeted-therapeutics>